These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26302810)

  • 1. HIV-1 TAT and IMMUNE DYSREGULATION in AIDS PATHOGENESIS: a THERAPEUTIC TARGET.
    Chiozzini C; Toschi E
    Curr Drug Targets; 2016; 17(1):33-45. PubMed ID: 26302810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tat-Based Therapies as an Adjuvant for an HIV-1 Functional Cure.
    Jin H; Li D; Lin MH; Li L; Harrich D
    Viruses; 2020 Apr; 12(4):. PubMed ID: 32276443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human immunodeficiency virus-1 Tat protein: immunological facets of a transcriptional activator.
    Gupta S; Mitra D
    Indian J Biochem Biophys; 2007 Oct; 44(5):269-75. PubMed ID: 18341200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple effects of HIV-1 trans-activator protein on the pathogenesis of HIV-1 infection.
    Huigen MC; Kamp W; Nottet HS
    Eur J Clin Invest; 2004 Jan; 34(1):57-66. PubMed ID: 14984439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 Tat: Role in Bystander Toxicity.
    Ajasin D; Eugenin EA
    Front Cell Infect Microbiol; 2020; 10():61. PubMed ID: 32158701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific Inhibition of HIV Infection by the Action of Spironolactone in T Cells.
    Lacombe B; Morel M; Margottin-Goguet F; Ramirez BC
    J Virol; 2016 Dec; 90(23):10972-10980. PubMed ID: 27681137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine.
    Cafaro A; Tripiciano A; Sgadari C; Bellino S; Picconi O; Longo O; Francavilla V; Buttò S; Titti F; Monini P; Ensoli F; Ensoli B
    Expert Opin Biol Ther; 2015; 15 Suppl 1():S13-29. PubMed ID: 26096836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoflavonoids as Inhibitors of HIV-1 Replication by Targeting the Tat and NF-κB Pathways.
    Olmedo DA; López-Pérez JL; Del Olmo E; Bedoya LM; Sancho R; Alcamí J; Muñoz E; Feliciano AS; Gupta MP
    Molecules; 2017 Feb; 22(2):. PubMed ID: 28218730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Host Factors on the Regulation of Tat-Mediated HIV-1 Transcription.
    Mousseau G; Valente ST
    Curr Pharm Des; 2017; 23(28):4079-4090. PubMed ID: 28641539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probabilistic control of HIV latency and transactivation by the Tat gene circuit.
    Cao Y; Lei X; Ribeiro RM; Perelson AS; Liang J
    Proc Natl Acad Sci U S A; 2018 Dec; 115(49):12453-12458. PubMed ID: 30455316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tat is a multifunctional viral protein that modulates cellular gene expression and functions.
    Clark E; Nava B; Caputi M
    Oncotarget; 2017 Apr; 8(16):27569-27581. PubMed ID: 28187438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV latency reversing agents act through Tat post translational modifications.
    Khoury G; Mota TM; Li S; Tumpach C; Lee MY; Jacobson J; Harty L; Anderson JL; Lewin SR; Purcell DFJ
    Retrovirology; 2018 May; 15(1):36. PubMed ID: 29751762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 Tat Recruits HDM2 E3 Ligase To Target IRF-1 for Ubiquitination and Proteasomal Degradation.
    Remoli AL; Marsili G; Perrotti E; Acchioni C; Sgarbanti M; Borsetti A; Hiscott J; Battistini A
    mBio; 2016 Oct; 7(5):. PubMed ID: 27795392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of HIV-1 Tat Protein Interactions with Host Receptors in HIV Infection and Pathogenesis.
    Cafaro A; Schietroma I; Sernicola L; Belli R; Campagna M; Mancini F; Farcomeni S; Pavone-Cossut MR; Borsetti A; Monini P; Ensoli B
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory Role of Complement Proteins in the Neuropathology Associated with Opiate Abuse and HIV-1 Co-Morbidity.
    Mahajan SD; Aalinkeel R; Parikh NU; Jacob A; Cwiklinski K; Sandhu P; Le K; Loftus AW; Schwartz SA; Quigg RJ; Alexander JJ
    Immunol Invest; 2017 Nov; 46(8):816-832. PubMed ID: 29058550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 regulatory proteins: targets for novel drug development.
    Ptak RG
    Expert Opin Investig Drugs; 2002 Aug; 11(8):1099-115. PubMed ID: 12150704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of HIV-1 gene expression and transcription.
    Baba M
    Curr Top Med Chem; 2004; 4(9):871-82. PubMed ID: 15134546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HIV-1 Tat Protein: Mechanism of Action and Target for HIV-1 Cure Strategies.
    Rice AP
    Curr Pharm Des; 2017; 23(28):4098-4102. PubMed ID: 28677507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathway analysis in HEK 293T cells overexpressing HIV-1 tat and nucleocapsid.
    Lee MJ; Park JH
    J Microbiol Biotechnol; 2009 Oct; 19(10):1103-8. PubMed ID: 19884766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.